Shire unveiled top-line data from new studies suggesting it's safe for Fabry disease patients to switch to Replagal from Genzyme's Fabrazyme, which has been running scarce for some time. In addition, it's safe for Gaucher disease patients to switch to Shire's Vpriv from Genzyme's Cerezyme. Shire release